Skip to content

Subscriptions are live: We're on the subscription model now, early-access price $24.99/month, with day, week, and longer plans too. New accounts start with 5 free premium days. Prefer to donate? Donations grant premium time and are logged on your profile page.

$KLRS

Kalaris Therapeutics, Inc. Common Stock

XNAS

$3.97
-1.59%-$0.064
RVOL peak today
Normal
Halted today
None today
Float
ultra-low
Next earnings
Unscheduled
$3.97-1.59%$0.0640Prev $4.03LIVE Full chart Live alerts
No recent price bars, the chart lights up when KLRS starts printing.

Why is KLRS down today? It is at $3.97 (-1.59%), and our scanner flagged it 2 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment KLRS spikes, and full due diligence on KLRS — key stats, earnings, dilution and insider activity. Free.

Free alerts

Get free $KLRS alerts the moment volume spikes

Our scanner flagged $KLRS 2 times in the last 30 days. Create a free account to track $KLRS, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.

Real-time RVOL & momentum alerts Personal watchlist & price alerts
Sign up free with email

No card · 5 premium days · join 800+ traders

Key Stats

Price & performance
Price
$3.97
Change today
-1.59%
Previous close
$4.03
52-week range
$3.03 – $11.88
Valuation & dividend
Market cap
$96M
Ownership & volume
Shares outstanding
23.8M
SEC · as of 2026-08-04 · 27d
Insider ownership
67.0%
DEF 14A · 2026-04-24
Institutional own.
77.00%
Total held
100.0%
Short interest
393K
▼ -4% vs prior · as of 2026-08-14
Days to cover
6.2d
Avg daily volume
201K
Classification
Exchange
XNAS
Relative volumevs this time of day
5m
2.1x
15m
0.5x
1h
0.5x
1D
0.2x

Get free KLRS + market alerts in your inbox

The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.

No spam. Unsubscribe anytime. Not investment advice.

Why is $KLRS down today?

Here is the latest on KLRS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KLRS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.

Likely catalystKalaris Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →Latest filing4Insider trade (Form 4)Aug 28, 2026 · 3 days ago
Why is $KLRS moving? →▶ Replay the moveAuto-generated from live scanner data. Not investment advice.
Trading profile⚡ Ultra-low floatShortableEasy to borrowNo SSRBorrow via Alpaca · SSR from Reg SHO 201
Wall Street consensusStrong Buy4 analysts
Avg target $15.50(+291% upside)
Range $14 - $17
4 buy0 hold0 sell

Analyst data via Nasdaq. Not investment advice.

Insiders

2 open-market buys0 buys, 0 sells last 3 months (4/2 over 12 months)
Show 7 recent transactions
InsiderActionShares% of positionOwns afterValueDate
Akkaraju Srinivas
Director
Bought (open market)+244K
1.0% of company
added 12%2.22M$1.2M
at $4.83
May 20, 26
Akkaraju Srinivas
Director
Sold (automatic/other)-67K
0.3% of company
sold 0.6%10.66Mn/aMay 20, 26
Akkaraju Srinivas
Director
Acquired (grant/award)+19K
0.08% of company
added 0.2%12.92Mn/aMay 20, 26
Hagen Brett R
Officer
Sold (automatic/other)-2Kn/an/a$13K
at $6.72
Mar 20, 26
Akkaraju Srinivas
Director
Acquired (grant/award)+1.50M
6.3% of company
added 13%12.95M$15.0M
at $10.00
Dec 22, 25
Akkaraju Srinivas
Director
Bought (open market)+480K
2.0% of company
added 3.8%12.95M$5.0M
at $10.42
Dec 18, 25
Hagen Brett R
Officer
Sold (automatic/other)-907sold 32%2K$8K
at $8.97
Mar 26, 25

Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.

$KLRS is down 1.6% today and has an active shelf on file. See who may be selling into moves →

Dilution watch

Active shelf

At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing). If $KLRS runs, these filings show who may be positioned to sell new or newly-registered shares into the move.

Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.

$KLRS Sentiment

Bullish
Bearish60Bullish
📰 News: 3 bull · 1 bearToday: -1.6%👥 Community: 0 bull · 0 bear

Blend of news sentiment, today’s move, and community votes. Not investment advice.

$KLRS Activity

News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.

News· GlobeNewswire Inc.· 6h ago Bullish
Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference
News· SEC EDGAR· 19d ago
Kalaris Therapeutics, Inc.: Q2 FY2026 results, three months to Jun 30, 2026
News· SEC EDGAR· 20d ago
Kalaris Therapeutics, Inc.: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Alert· 26d ago +10.6% vs EMA
KLRS 200EMA (5m) Trending · 54 bars · L3 · +10.60% above EMA · slope +2.28%
at $4.33
Alert· 26d ago +7.1% vs EMA
KLRS 200EMA (1m) Trending · 93 bars · L3 · +7.10% above EMA · slope +1.68%
at $4.33
Alert· 26d ago +7.1% vs EMA
KLRS 200EMA (1m) Trending · 93 bars · L3 · +7.10% above EMA · slope +1.68%
at $4.33
Alert· 26d ago +7.1% vs EMA
KLRS 200EMA (1m) Trending · 93 bars · L3 · +7.10% above EMA · slope +1.68%
at $4.33
Alert· 26d ago +2.4% vs EMA
KLRS 50EMA (5m) Trending · 54 bars · L3 · +2.45% above EMA · slope +2.66%
at $4.33
Alert· 27d ago 4.4× RVOL
KLRS hit 4.401x RVOL at 1:03 PM ET
at $4.29
Alert· 27d ago +1.89%
$KLRS moved +1.89% in 1 min (Level 1) at 10:59 AM ET
at $4.31
News· GlobeNewswire Inc.· 27d ago Bearish
SDEV: Abbott Cooper PLLC Announces Investigation on Behalf of Stablecoin Development Corporation (Formerly Novabay Pharmaceuticals, Inc.) Stockholders
Alert· 42d ago -1.23%
$KLRS moved -1.23% in 1 min (Level 1) at 2:45 PM ET
at $4.07
Alert· 42d ago 2.5× RVOL
KLRS hit 2.515x RVOL at 2:45 PM ET
at $4.07
News· SEC EDGAR· 42d ago
Kalaris Therapeutics, Inc. filed an 8-K: Executive / Board Change
News· SEC EDGAR· 45d ago
Kalaris Therapeutics, Inc. filed an 8-K: Regulation FD Disclosure, Other Material Event
News· GlobeNewswire Inc.· 45d ago Bullish
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
News· GlobeNewswire Inc.· 69d ago Bullish
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Also moving today

The tickers our scanner is lighting up most over the last 48 hours.

KLRS stock FAQ

Why is $KLRS down today?

Here is the latest on KLRS from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for KLRS today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.

What is the KLRS stock price today?

KLRS last traded at $3.97, down 1.59% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).

Where can I see live KLRS alerts?

The KLRS Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged KLRS 2 times in the last 30 days.

What exchange is KLRS on?

KLRS (Kalaris Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $96M.

Is KLRS good for day trading?

That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge KLRS for yourself. This is not investment advice.

Live data from TheDesperateTrader scanner. Not investment advice.